Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "hold" rating re-affirmed by analysts at TD Cowen.
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update [Yahoo! Finance]
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update